Measure for Funding the Development of BioFoam(TM) was Passed by the U.S. House of Representatives
July 01 2004 - 10:58AM
PR Newswire (US)
Measure for Funding the Development of BioFoam(TM) was Passed by
the U.S. House of Representatives Innovative Therapy From CryoLife
is Designed to Control Bleeding of Severe Wounds ATLANTA, July 1
/PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE:CRY), a bio-surgical
device and human tissue processing company, announced today that a
recommendation to provide $1 million to fund the development of
BioFoam(TM) was recently passed by the U.S. House of
Representatives. U.S. Rep. Phil Gingrey, a member of the House
Armed Services Committee, introduced the measure, which was
included in the Department of Defense Appropriations Act (H.R.
4613) for Fiscal 2005. This funding will now go before a Conference
Committee between the U.S. House of Representatives and the U.S.
Senate. BioFoam, a protein hydrogel adhesive in the pre-clinical
stage of development, contains an expansion agent that sets quickly
and rapidly arrests bleeding of large vessel injuries. BioFoam is
based on the same technology as BioGlue,(R) approved by the U.S.
Food and Drug Administration to control bleeding as an adjunct to
sutures and staples for use in open surgical repair of large
vessels. BioGlue is also CE marked in the European Community and
approved in Canada for use in soft tissue repair. "The development
and potential use of BioFoam on the battlefield holds great promise
for members of our armed forces who suffer serious wounds in
combat," said Rep. Phil Gingrey. "Making available the most
advanced medical technologies for saving the lives of the men and
women who serve our country under hostile conditions is a high
priority." "Without the support of the Georgia delegation,
especially Congressman Gingrey, this funding, which was passed by
the U.S. House of Representatives to develop BioFoam would not have
been possible," stated Steven G. Anderson, President and Chief
Executive Officer of CryoLife, Inc. About CryoLife, Inc. Founded in
1984, CryoLife, Inc. is a leader in the processing and distribution
of implantable living human tissues for use in cardiovascular and
vascular surgeries throughout the United States and Canada. The
Company's BioGlue Surgical Adhesive is FDA approved as an adjunct
to sutures and staples for use in adult patients in open surgical
repair of large vessels and is CE marked in the European Community
and approved in Canada for use in soft tissue repair and approved
in Australia for use in vascular and pulmonary sealing and repair.
The Company also manufactures the SG Model #100 vascular graft,
which is CE marked for distribution within the European Community.
Statements made in this press release that look forward in time or
that express management's beliefs, expectations or hopes are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. These future events may
not occur as and when expected, if at all, and, together with the
Company's business, are subject to various risks and uncertainties.
These risks and uncertainties include that BioFoam may prove
ineffective or may not be commercially feasible, that the funding
recommendation passed by the House of Representatives does not
receive final approval, that the Company's aggregate 2004 revenues
and expenses may not meet its expectations, that demand for
CryoLife preserved tissues may not return to prior levels, the
possibility that the FDA could impose additional restrictions on
the Company's operations, require a recall, or prevent the Company
from processing and distributing tissues or manufacturing and
distributing other products, that the Company may not have
sufficient borrowing or other capital availability to fund its
business, that present and future litigation may be resolved only
by substantial payments by the Company in excess of available
insurance coverage and amounts set aside for products liability
cases, the possibility of severe decreases in the Company's
revenues and working capital, that to the extent the Company does
not have sufficient resources to pay the claims against it, it may
be forced to cease operations or seek protection under applicable
bankruptcy laws, changes in laws and regulations applicable to
CryoLife and other risk factors detailed in CryoLife's Securities
and Exchange Commission filings, including CryoLife's Form 10-K
filing for the year ended December 31, 2003, and the Company's
other SEC filings. The Company does not undertake to update its
forward-looking statements. For additional information about the
company, visit CryoLife's Web site: http://www.cryolife.com/
Contact: Joseph T. Schepers Vice President, Corporate
Communications 770-419-3355 DATASOURCE: CryoLife, Inc. CONTACT:
Joseph T. Schepers, Vice President, Corporate Communications of
CryoLife, Inc., +1-770-419-3355 Web site: http://www.cryolife.com/
Copyright
CryoLife (NYSE:CRY)
Historical Stock Chart
From Jun 2024 to Jul 2024
CryoLife (NYSE:CRY)
Historical Stock Chart
From Jul 2023 to Jul 2024